Home › Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a...
 

Keywords :   


Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a...

2014-01-23 08:48:30| Biotech - Topix.net

Alnylam Pharmaceuticals , Inc. , a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 study with ALN - AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin for the treatment of hemophilia and rare bleeding disorders .

Tags: a trial phase clinical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09Atlantic Tropical Weather Outlook
30.09Eastern North Pacific Tropical Weather Outlook
30.09Does Chinese investment benefit or damage Ireland?
29.09Tropical Depression Twelve Public Advisory Number 1
29.09Summary for Tropical Depression Twelve (AT2/AL122024)
29.09Tropical Depression Twelve Wind Speed Probabilities Number 1
29.09Tropical Storm Joyce Forecast Discussion Number 10
29.09Tropical Depression Twelve Forecast Discussion Number 1
More »